Afinitor is a brand name for the drug everolimus, an oral inhibitor of the mechanistic target of rapamycin complex 1 signaling pathway. It is primarily used to treat certain types of kidney cancer, neuroendocrine tumors, and to prevent organ transplant rejection. By blocking mtorc1 activity, everolimus reduces cell proliferation and angiogenesis that drive tumor growth and immune activation. This inhibition slows the growth of malignant cells and helps maintain graft stability by dampening the host immune response. Physiologically, the medication interferes with nutrient sensing pathways that regulate protein synthesis and metabolism, leading to decreased cell cycle progression. Consequently, patients experience reduced tumor burden or prolonged graft survival without the need for more aggressive chemotherapy or immunosuppression.

Afinitor is a medication that contains the drug everolimus and is used to treat certain types of cancer. It belongs to a class of drugs known as mtor inhibitors which modulate cellular signaling pathways. The drug works by binding to specific proteins that regulate cell growth and survival. This binding blocks the activity of the mtor pathway leading to reduced proliferation of abnormal cells. By slowing the division of malignant cells Afinitor helps control tumor progression. It also diminishes the formation of new blood vessels that tumors need to grow. The overall effect is a decrease in cancer cell expansion and a prolongation of disease stabilization. Overall Afinitor's pharmacological profile reflects its ability to target molecular mechanisms that drive tumor biology without directly killing cells.

Afinitor may cause skin rash in some patients. It can lead to elevated blood lipid levels. Some individuals experience mild fever without infection. Gastrointestinal discomfort such as nausea is possible. Fatigue is reported by a minority of users. Laboratory tests may show changes in kidney function markers.

Fatigue is among the most frequently reported side effects of Afinitor. Nausea and diarrhea are common gastrointestinal occurrences associated with the drug. Skin reactions such as rash or acne-like eruptions may develop during treatment. Elevations in cholesterol and triglyceride levels have been observed in some patients. Infection risk can increase because the medication modulates immune function. Less commonly, changes in blood cell counts and elevated liver enzymes may appear.